Cytosorbents (NASDAQ:CTSO) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Cytosorbents (NASDAQ:CTSO) in a report released on Monday morning. The firm issued a hold rating on the medical research company’s stock.

Other equities research analysts have also issued research reports about the company. HC Wainwright reissued a “neutral” rating and issued a $1.00 target price on shares of Cytosorbents in a research note on Monday, November 11th. D. Boral Capital reiterated a “buy” rating and issued a $10.00 price objective on shares of Cytosorbents in a research report on Friday, January 3rd. Two analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Cytosorbents presently has an average rating of “Moderate Buy” and an average price target of $4.67.

Cytosorbents Price Performance

Shares of NASDAQ:CTSO opened at $1.05 on Monday. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06. The stock has a market cap of $57.41 million, a PE ratio of -2.92 and a beta of 0.58. The company’s fifty day moving average is $0.92 and its 200 day moving average is $1.03. Cytosorbents has a 52 week low of $0.70 and a 52 week high of $1.59.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Sargent Investment Group LLC raised its holdings in Cytosorbents by 4.9% in the 2nd quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock worth $1,008,000 after purchasing an additional 67,181 shares in the last quarter. Atomi Financial Group Inc. purchased a new position in shares of Cytosorbents during the third quarter valued at about $51,000. Finally, Geode Capital Management LLC raised its stake in Cytosorbents by 7.5% in the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after buying an additional 32,415 shares in the last quarter. Institutional investors own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.